Pu Junlin, Yan Xiuli, Zhang Hui
Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
J Adv Res. 2024 Nov 29. doi: 10.1016/j.jare.2024.11.032.
Gastric cancer (GC) is a global health concern, contributing significantly to cancer-related mortality rates. Early detection is vital for improving patient outcomes. Recently, circular RNAs (circRNAs) have emerged as crucial players in the development and progression of various cancers, including GC.
This comprehensive review underscores the promising potential of circRNAs as innovative biomarkers for the early diagnosis of GC, as well as their possible utility as therapeutic targets for this life-threatening disease. Specifically, the review focuses on recent findings, mechanistic insights, and clinical applications of circRNAs in GC.
Dysregulation of circRNAs has been consistently observed in GC tissues, offering potential diagnostic value due to their stability in bodily fluids such as blood and urine. For instance, circPTPN22 and hsa_circ_000200. Furthermore, the expression levels of circRNAs such as circCUL2, hsa_circ_0000705 and circSHKBP1 have shown strong associations with critical clinical features of GC, including diagnosis, prognosis, tumor size, lymph node metastasis, tumor-node-metastasis (TNM) stage, and treatment response. Additionally, circRNAs such as circBGN, circLMO7, and circMAP7D1 have shown interactions with specific microRNAs (miRNAs), proteins, and other molecules that play key roles in development and progression of GC. This further highlighting their potential as therapeutic targets. Despite their potential, several challenges need to be addressed to effectively apply circRNAs as GC biomarkers. These include standardizing detection methods, establishing cutoff values for diagnostic accuracy, and validating findings in larger patient cohorts. Moreover, the functional mechanisms by which circRNAs contribute to GC pathogenesis and therapeutic resistance warrant further investigation. Advances in circRNAs research could provide valuable insights into the early detection and targeted treatment of GC, ultimately improving patient outcomes.
胃癌（GC）是一个全球关注的健康问题，对癌症相关死亡率有重大影响。早期检测对于改善患者预后至关重要。最近，环状RNA（circRNAs）已成为包括胃癌在内的各种癌症发生和发展的关键因素。
本综述强调了circRNAs作为胃癌早期诊断的创新生物标志物的潜在前景，以及它们作为这种危及生命疾病的治疗靶点的可能效用。具体而言，该综述重点关注circRNAs在胃癌中的最新发现、机制见解和临床应用。
在胃癌组织中一直观察到circRNAs的失调，由于它们在血液和尿液等体液中的稳定性，具有潜在的诊断价值。例如，circPTPN22和hsa_circ_000200。此外，circCUL2、hsa_circ_0000705和circSHKBP1等circRNAs的表达水平与胃癌的关键临床特征密切相关，包括诊断、预后、肿瘤大小、淋巴结转移、肿瘤-淋巴结-转移（TNM）分期和治疗反应。此外，circBGN、circLMO7和circMAP7D1等circRNAs已显示与在胃癌发生和发展中起关键作用的特定微小RNA（miRNAs）、蛋白质和其他分子相互作用。这进一步突出了它们作为治疗靶点的潜力。尽管它们具有潜力，但要有效地将circRNAs用作胃癌生物标志物，仍需解决几个挑战。这些挑战包括标准化检测方法、确定诊断准确性的临界值，以及在更大的患者队列中验证研究结果。此外，circRNAs促进胃癌发病机制和治疗耐药性的功能机制值得进一步研究。circRNAs研究的进展可为胃癌的早期检测和靶向治疗提供有价值的见解，最终改善患者预后。
